ELUT - Elutia Inc Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ELUT

ELUTIA INC

NASDAQ

$0.77

▼ DOWN 1.61% (-0.01)

KEY STATISTICS

Market Cap$34.42 M

52w High$1.39

52w Low$0.50

Dividend Yield—

Frequency—

P/E-1.56

Volume84.83K

Shares Out.44.21M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

C. Randal Mills

COMPENSATION 2026

Salary$600,000

Stock Awards$0

Incentive Plan Pay$738,000

All Other Comp.$6,284

Total$1,344,284

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 7, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$10.50

Target Low$5.00

Target Median$10.00

Target Consensus$8.88

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$1.00M

NOV

THU

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

PRICE

$0.77 ▼ DOWN 1.61% (−$0.01)

About Elutia Inc

https://elutia.com ↗

Elutia Inc. develops and commercializes drug-eluting biologics for neurostimulation, wound care, and breast reconstruction, serving hospitals with products like CanGaroo, ProxiCor, Tyke, VasCure, and SimpliDerm across device protection, women’s he...

INDUSTRY

Biotechnology

A PRODUCT ELUTIA INC IS KNOWN FOR

SimpliDerm

SimpliDerm, a hydrated human acellular dermal matrix for soft-tissue reconstruction, is Elutia’s flagship product, now its primary focus after selling its bioenvelope business to Boston Scientific.

COMPETITORS

COMPETITOR

Elutia in 2025

SENTIMENT: + POSITIVE

ACQUISITION · Q3 2025

Elutia Inc. Sells BioEnvelope Business to Boston Scientific for $88 Million to Fuel Future Growth

In a significant strategic move, Elutia Inc. completed the sale of its BioEnvelope business to medical device giant Boston Scientific for $88 million. This divestiture provided a substantial capital infusion, allowing Elutia to eliminate its debt and fully fund the development and launch of its next-generation NXT-41x platform for plastic and reconstructive surgery.

DIVESTITURE · Q3 2025 · COMPLETED

Elutia Divests BioEnvelope Business to Boston Scientific for $88 Million to Fuel Next-Generation Biomatrix Platform

Elutia Inc. completed the sale of its BioEnvelope business to Boston Scientific Corporation in a strategic move to reshape its focus and financial standing. The divestiture provides capital to eliminate debt and fully fund the development and launch of its NXT-41x platform, targeting the $1.5 billion plastic and reconstructive surgery market.

Latest News

GLOBENEWSWIRE · OCT 1, 2026

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestiture The Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE: BSX).

READ ARTICLE